Advertisement
Advertisement

IONS

IONS logo

Ionis Pharmaceuticals, Inc. Common Stock

86.51
USD
Sponsored
+3.03
+3.63%
Feb 06, 15:59 UTC -5
Closed
exchange

After-Market

86.49

-0.02
-0.02%

IONS Earnings Reports

Positive Surprise Ratio

IONS beat 28 of 40 last estimates.

70%

Next Report

Date of Next Report
Feb 17, 2026
Estimate for Q4 25 (Revenue/ EPS)
$158.47M
/
-$1.33
Implied change from Q3 25 (Revenue/ EPS)
+0.94%
/
+66.25%
Implied change from Q4 24 (Revenue/ EPS)
-30.19%
/
+101.52%

Ionis Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On Oct 29, 2025, IONS reported earnings of -0.80 USD per share (EPS) for Q3 25, beating the estimate of -1.25 USD, resulting in a 36.42% surprise. Revenue reached 157.00 million, compared to an expected 133.54 million, with a 17.57% difference. The market reacted with a -2.30% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 20 analysts forecast an EPS of -1.33 USD, with revenue projected to reach 158.47 million USD, implying an increase of 66.25% EPS, and increase of 0.94% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Ionis Pharmaceuticals, Inc. Common Stock reported EPS of -$0.80, beating estimates by 36.42%, and revenue of $157.00M, 17.57% above expectations.
The stock price moved down -2.3%, changed from $73.57 before the earnings release to $71.88 the day after.
The next earning report is scheduled for Feb 17, 2026.
Based on 20 analysts, Ionis Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$1.33 and revenue of $158.47M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement